- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04388371
Glutamine PET Imaging in LAM
Study Overview
Detailed Description
Objectives This is a hypothesis-driven prospective pilot study of the targeted PET reagent 11C-Glutamine in LAM.
The objective is to test the hypothesis that 11C-Glutamine PET/CT will demonstrate uptake within the lungs and/or associated neoplasm of patients with LAM and that this effect will be modified by treatment with mTOR inhibitors.
Rationale Our rationale is that 11C-Glutamine PET/CT may provide an improved ability to diagnose LAM, as well as predict and monitor treatment response to mTOR inhibitors.
Aims Test the hypothesis that 11C-Gln PET imaging of the lungs in humans will reflect the known "glutamine addiction" seen in mechanistic preclinical studies of LAM. As a result, PET imaging will show increased tracer uptake in affected areas of diseased lungs and will show reduced uptake after initiating treatment with mTOR inhibitors.
Approach: We will evaluate 11C-Glutamine PET/CT uptake in patients with known LAM, and if possible, we will test subjects again after 8 weeks of mTOR inhibitor therapy (either sirolimus or everolimus).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female subjects
- ≥ 18 years of age
Diagnosis of LAM via either a. Histopathologic diagnosis b. Compatible CT chest and one of the following i. Tuberous Sclerosis Complex* ii. Angiomyolipoma or lymphangioma iii. Chylous Effusion iv. Serum VEGF-D level >800 pg/mL
- The diagnosis of TSC will be based on the presence of at least two major criteria or one major and one or more minor features per published guidelines.(30)
Exclusion Criteria:
- Patients with any known intrathoracic cancer (primary lung cancer or metastatic disease) or undergoing active treatment for malignancy
- Patients with use of investigational therapies for LAM either currently or in the prior 3 months
- Patients with body weight ≥400 pounds or body habitus or disability that will not permit the imaging protocol to be performed
- Patients known to be pregnant or breastfeeding
- Patients with clinically active known or suspected pulmonary infection of any type
- Patients known or suspected to have any inborn error of metabolism
- Patients with known type I diabetes mellitus
- Patients who cannot have a peripheral IV for any reason
- Patients who cannot lie flat for the duration of the PET scan
- Patients who are claustrophobic
- Patients with a prior allergy to contrast agents or to PET tracers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prior to subject taking sirolimus or everolimus
To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
|
Glutamine will be administered by IV injection prior to PET imaging.
|
Experimental: subjects taking sirolimus or everolimus
To compare images from subjects prior to use of sirolimus or everolimus to images produced after use of sirolimus or everolimus.
|
Glutamine will be administered by IV injection prior to PET imaging.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the uptake of the PET tracer throughout the entire lung and any associated neoplasms (AML, Lymphangiomas) in patients with LAM
Time Frame: 8 weeks
|
While these imaging techniques have not been used in normal populations, the pulmonary uptake of patients with known intraabdominal malignancy will serve as control for evaluation of any potential uptake.
When comparing treatment effects, each patient can serve as their own control as they will have already had imaging completed prior to the initiation of therapy.
VEGF-D levels will be collected from clinical laboratory assessment or will be collected at time of enrollment, and relative elevation of VEGF-D will be compared to the relative uptake of tracer within the pulmonary parenchyma of each individual patient.
|
8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Timothy S Blackwell, MD, Vanderbilt University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 190481
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphangioleiomyomatosis (LAM)
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosis (LAM)United States
-
University of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI); The LAM Foundation; National...RecruitingLymphangioleiomyomatosis | LAMUnited States
-
Schön Klinik Berchtesgadener LandCompletedLymphangioleiomyomatosis | Pulmonary Rehabilitation | LAMGermany
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
Baylor College of MedicineUniversity of South Florida; National Institutes of Health (NIH); Brigham and... and other collaboratorsTerminatedPulmonary LymphangioleiomyomatosisUnited States
-
Tony EissaUniversity of Texas; University of CincinnatiCompletedPulmonary LymphangioleiomyomatosisUnited States
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosisFrance, United States, Italy
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
Peking Union Medical College HospitalXiangya Hospital of Central South University; Shanghai Zhongshan Hospital; West... and other collaboratorsRecruiting
-
University of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingLymphangioleiomyomatosisUnited States
Clinical Trials on Glutamine
-
University of AlbertaCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI)TerminatedPain | Head and Neck Cancer | Cancer-related Problem/ConditionCanada, United States
-
Emmaus Medical, Inc.Completed
-
Daren K. HeylandCanadian Institutes of Health Research (CIHR)Active, not recruitingBurnsUnited States, Belgium, Canada, Singapore, Spain, Austria, Brazil, Dominican Republic, Germany, Italy, Paraguay, Sweden, Thailand, United Kingdom
-
Eastern Regional Medical CenterTSPC America, Inc.WithdrawnPeripheral NeuropathyUnited States
-
Banaras Hindu UniversityCompleted
-
Hawaii Pacific HealthUnknown
-
Tulane UniversityCompletedDiarrhea-Predominant Irritable Bowel SyndromeUnited States
-
AHS Cancer Control AlbertaCross Cancer InstituteWithdrawnColorectal Cancer | Metastasis | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal
-
University of Missouri, Kansas CityUnited States Department of DefenseCompletedHemorrhagic ShockUnited States